450 related articles for article (PubMed ID: 20671739)
1. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
4. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
5. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
6. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068
[TBL] [Abstract][Full Text] [Related]
7. Are new vitamin D analogues in renal bone disease superior to calcitriol?
Salusky IB
Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
[TBL] [Abstract][Full Text] [Related]
8. Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.
Gesek FA; Desmond JS
Nephrol Nurs J; 2008; 35(2 Suppl):5S-22S; quiz 23S. PubMed ID: 18505229
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D in Chronic Kidney Disease and Dialysis Patients.
Jean G; Souberbielle JC; Chazot C
Nutrients; 2017 Mar; 9(4):. PubMed ID: 28346348
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.
Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V
Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147
[TBL] [Abstract][Full Text] [Related]
12. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.
Coen G; Mantella D; Manni M; Balducci A; Nofroni I; Sardella D; Ballanti P; Bonucci E
Kidney Int; 2005 Oct; 68(4):1840-8. PubMed ID: 16164662
[TBL] [Abstract][Full Text] [Related]
13. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.
Coyne DW; Goldberg S; Faber M; Ghossein C; Sprague SM
Clin J Am Soc Nephrol; 2014 Sep; 9(9):1620-6. PubMed ID: 24970869
[TBL] [Abstract][Full Text] [Related]
14. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM
Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737
[TBL] [Abstract][Full Text] [Related]
15. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
[TBL] [Abstract][Full Text] [Related]
16. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
17. Calcimimetics versus vitamin D: what are their relative roles?
Drüeke TB
Blood Purif; 2004; 22(1):38-43. PubMed ID: 14732810
[TBL] [Abstract][Full Text] [Related]
18. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E
Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]